We request information in relation to the following medicines which are marketed for the treatment of chronic obstructive pulmonary disease:
- Anoro (vilanterol and umeclidinium) which is marketed by GlaxoSmithKline
- Braltus (tiotropium) which is marketed by Teva
- Duaklir (aclidinium bromide and formoterol fumarate dihydrate) which is marketed by Astra Zeneca
- Eklira (aclidinium) which is marketed by Astra Zeneca
- Incruse (umeclidinium) which is marketed by GlaxoSmithKline
- Seebri (glycopyrronium) which is marketed by Novartis
- Spiolto (tiotropium and olodaterol) which is marketed by Boehringer Ingelheim
- Spiriva (tiotropium) which is marketed by Boehringer Ingelheim
- Trimbow (formoterol fumarate dihydrate, beclometasone dipropionate and glycopyrronium (as bromide) which is marketed by Chiesi
- Ultibro (indacaterol and glycopyrronium) which is marketed by Novartis or Pfizer
(the “COPD Medicines”).
In respect of each of the COPD Medicines, please could you provide us with the following information:
1. A copy of any agreement relating to a rebate, discount, patient access, risk-sharing or other pricing scheme entered into by Calderdale CCG in relation to the COPD Medicines which results in Calderdale CCG paying less than the NHS list price for such COPD Medicines (whether by way of discount, rebate etc).
NHS Calderdale CCG does not have any agreements in place in relation to the COPD medicines listed.
2. A copy of any communications between Calderdale CCG and the company or companies marketing such COPD Medicine in relation to such scheme
3. Any information or requests sent to GP practices comprised within the CCG in the 6 months since contract signature with respect to such COPD Medicines schemes